The Food and Drug Administration Modernization Act (FDAMA) requires that manufacturers track certain devices when the agency orders them to do so. Tracking is intended to facilitate notification and recall in the event a device presents a serious risk to health that requires prompt attention. This revised guidance announces that Thoracic Aortic Aneurysm (TAA) stent grafts have been added to the list of devices subject to medical device tracking requirements.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in agency guidances means that something is suggested or recommended, but not required.

For FDA guidance, go to:

http://www.fda.gov/cdrh/comp/guidance/169.html

More Industry Headlines